Atellica CH Urine Albumin (UAlb). Material Number: 11537225 Recall
Atellica CH Urine Albumin (UAlb). Material Number: 11537225
FDA recall Class II
Ongoing
FDA lists this Class II recall for Atellica CH Urine Albumin (UAlb). Material Number: 11537225. Review the affected identifiers, reported reason and manufacturer instructions below.
Recall at a glance
- Recall number
- Z-1484-2026
- Recall classification
- Class II
- Enforcement status
- Ongoing
- Initiation date
- Jan 20, 2026
- FDA report date
- Mar 11, 2026
- Quantity in commerce
- 4,885 units
- Distribution
- See key details
- FDA cause
- Under Investigation by firm
What is being recalled?
Atellica CH Urine Albumin (UAlb). Material Number: 11537225
Affected model & UDI checker
Search the exact identifiers published for Z-1484-2026.
The lookup covers structured identifiers listed on this page. A full UDI may also contain lot or serial information; a GTIN match alone does not check those conditions.
Affected products
| Model / catalog number | Product | Lot scope reported | UDI / GTIN |
|---|---|---|---|
| Not specified | Atellica CH Urine Albumin (UAlb). Material Number: 11537225 | Check source notice | 00630414611099 |
FDA code information
Material Number: 11537225. UDI-DI: 00630414611099. Lot Numbers: All lot numbers.
Why was this product recalled?
Falsely depressed UAlb patient results may occur. Affected samples with any urine albumin concentration above the UAlb measuring interval >40.0 mg/dL may report values between 6.2 mg/dL and 40.0 mg/dL.
What actions did Siemens Healthcare Diagnostics, Inc. take?
Siemens Healthineers notified consignees on about 01/20/2026 via mailed FedEx letter titled Urgent Medical Device Correction. Consignees were informed that as temporary mitigation, for any sample with a UAlb result above 5.0 mg/dL (50 mg/L), reanalyze the sample with a x10 dilution. If the diluted result is consistent with the initial result, either result may be reported. If the diluted result is inconsistent with the initial result, the diluted result should be reported. If you prefer to automate this dilution, please refer to your internal laboratory procedures. Consignees were instructed to review the notification with their Medical Director to determine the appropriate course of action, including evaluation of any previously generated results, if applicable, and complete and return the provided Field Correction Effectiveness Check Form. A follow-up communication will be provided when Customer Actions are no longer required.
Read the manufacturer action recorded by FDARecall timeline
Recall initiated by firm
FDA notice posted
FDA classification recorded
FDA enforcement report date
Related FDA submissions
No submission number with an exact verified relationship is linked in the retrieved recall notice.
FDA’s notice explicitly links the submission numbers shown here. Read each filing for its own recorded device and scope.
Source and update history
- FDA recall notice Z-1484-2026
- openFDA enforcement record · Source release Nov 11, 2026 · Retrieved Nov 21, 2026
- openFDA device recall record · Source release Nov 19, 2026 · Retrieved Nov 21, 2026
- FDA enforcement data
First stored snapshot of this source.
- FDA device-recall notice
First stored snapshot of this source.
The history starts with the versions held by MedtechLedger. Earlier source changes are not reconstructed. Official dates and recorded status come from FDA; page summaries describe the source information.
Our data sources and methodology